Obalon Therapeutics Inc., a San Diego-based drug startup, has secured $4.7 million of a 7.7 million Series A round, according to a regulatory filing. Domain Associates led the deal, and was joined by Okapi Ventures and Phagia Technology Inc. The company does not have a website.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.